Psychopharmacological treatment of oppositional defiant disorder

CNS Drugs

Volumn 23, Issue 1, 2009, Pages 1-17

  Turgay, Atilla ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Toronto ADHD Clinic   (Canada)

Author keywords

Alpha 2 adrenergic receptor agonists, therapeutic use; Amfetamine, therapeutic use; Antidepressants, therapeutic use; Antipsychotics, therapeutic use; Atomoxetine, therapeutic use; Attention deficit and disruptive behaviour disorders, treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CARBAMAZEPINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; PEMOLINE; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGGRESSION; AGITATION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; HYPOTENSION; INCREASED APPETITE; INTERNATIONAL CLASSIFICATION OF DISEASES; LIVER DISEASE; MAJOR DEPRESSION; MENTAL INSTABILITY; MOOD DISORDER; OBESITY; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; SEIZURE THRESHOLD; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TIC; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ALGORITHMS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS;

EID: 57449083310     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200923010-00001     Document Type: Review

References (119)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
2. Barkley R. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: The Guilford Press, 2006
3. World Health Organization. International classification of diseases (ICD-10). Geneva: World Health Organization, 1994
4. Essau CA. Conduct and oppositional defiant disorders: epidemiology, risk factors and treatment. Mahwah (NJ): Lawrence Earlbaum Associates, 2003
5. Hinshaw SP. On the distinction between attentional deficit/hyperactivity and conduct problems/aggression in child psychopathology. Psychological Bulletin 1987; 101: 443-63
6. Ansari R, Turgay A, Ng D, et al. ADHD comorbidity in psychiatric disorders: subtype and gender relationships [poster]. In: New research abstracts: American Psychiatric Association Annual Meeting; 2004 May 1-6; New York. Arlington (VA): American Psychiatric Association, 2004: 89
7. Turgay A. Treatment of comorbidity in conduct disorder. Dir Psychiatry 2003; 23: 137-49
8. Turgay A, Joseph L, Nag SA, et al. Oppositional defiant disorder, conduct disorder and ADHD relationships [abstract]. Ontario Psychiatric Association Annual Scientific Conference; 2003 Jan 30; Toronto (ON)
9. Turgay A, Joseph L, Nag SA, et al. High risk of conduct and mood disorders in children and adolescents with ADHD and oppositional defiant disorder [abstract]. Ontario Psychiatric Association Annual Scientific Conference; 2003 Jan 28-30, Toronto (ON)
10. Turgay A. The aggressive and impulsive child: innovations in the assessment and treatment of attention deficit hyperactivity disorder and disruptive behaviour disorders. Paediatr Child Health 2004; 9 Suppl. 9: 3B
11. Turgay A. Aggression and disruptive behavior disorders in children and adolescents. Expert Rev Neurother 2004; 4 (4): 623-32
12. Turgay A. The diagnosis of disruptive behavior disorders. Paediatr Child Health 2004; 9 Suppl. B: 4-7B
13. Vitiello D, Jensen PS. Disruptive behavior disorders. In: Kaplan HI, Sadock BJ. Comprehensive textbook of psychiatry: IV. Vol. 2. Baltimore (MD): Williams and Wilkins, 1995: 2311-9
14. Ansari R, Turgay A, Ng D, et al. ADHD in child and adolescent psychiatric disorders: gender and subtype relationships [poster]. In: New research abstracts: American Psychiatric Association Annual Meeting; 2004 May 1-6; New York. Arlington (VA): American Psychiatric Association, 2004: 88
15. Biederman J, Faraone S, Milberger S, et al. A prospective four year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996; 53: 437-46
16. Lahey BB, Loeber R, Quay HC, et al. Oppositional defiant and conduct disorder: issues to be resolved for DSM -IV. J Am Acad Child Adolesc Psychiatry 1992; 29: 620-6
17. Turgay A, Ansari R, Schwartz M, et al. Comorbidity differences in ADHD throughout the life cycle [abstract]. Scientific and clinical report session of the American Psychiatric Association Annual Scientific Meeting; 2005 May 21-26; Atlanta (GA)
18. Herjanic B, Campbell W. Differentiating psychiatrically disturbed children on the basis of a structured interview. J Abnorm Child Psychol 1977; 5: 127-34
19. Shaffer D, Fisher P, Lucas CP, et al. Diagnostic interview schedule for children, version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnosis. J Am Acad Child Adolesc Psychiatry 2000; 39: 28-38
20. Ambrossini P, Metz C, Probucki K, et al. Videotape reliability of the third revised edition of the K-SADS. J Am Acad Child Adolesc Psychiatry 2000; 39: 49-58
21. Achenbach T. Assessment and taxonomy of child and adolescent psychopathology. Beverly Hills (CA): Sage, 1985
22. Offord DR, Boyle MH, Szatmari P, et al. Ontario child health study: II. Six-month prevalence of disorder and rates of service utilization. Arch Gen Psychiatry 1987; 44: 832-6
23. Gadow KD, Sprafkin J. Child symptom inventory. Stonybrook (NY): Checkmate Plus, 1987
24. Conners CK. Conners' rating scales revised: instruments for use with children and adolescents. North Tonawanda (NY): Multi Health Systems, 1997
25. Conners CK, Parker JDA, Citarenios G, et al. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1997; 26: 257-68
26. Turgay A. ADHD and disruptive behavior disorders screening and rating scale. West Bloomfield (MI): Integrative Therapy Institute, 1994
27. Harada Y, Saitoh K, Iida J, et al. The reliability and validity of the oppositional defiant behavior inventory. Eur Child Adolesc Psychiatry 2004; 13 (3): 185-90
28. Loeber R, Wung P, Keenan K, et al. Developmental pathways in disruptive child behavior. Dev Psychopathol 1993; 55: 102-33
29. Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children: prevalence in a large sample from general population. Arch Gen Psychiatry 1987; 44: 69-76
30. Faraone SV, Biederman J, Keenan K, et al. Separation of DSM-III attention deficit disorder and conduct disorder: evidence from a family genetic study of American child psychiatric patients. Psychol Med 1991; 21: 109-21
31. Loeber R. The natural histories of juvenile conduct problems, substance use and delinquency: evidence for developmental progressions. In: Lahey BB, Kazdin AE, editors. Advances in clinical child psychology. Vol. 2. New York: Plenum, 1998: 73-124
32. Walker LL, Lahey BB, Russo MF, et al. Anxiety, inhibition, and conduct disorder in children: I. Relations to social impairment. J Am Acad Child Psychiatry 1991; 30: 187-91
33. Lahey BB, Loeber R. Framework for a developmental model of oppositional defiant disorder and conduct disorder. In: Routh DK, editor. Disruptive behavior disorders in childhood. New York: Plenum, 1994: 139-80
34. Ferguson DM, Horwood LJ, Lynskey MT. Prevalence and comorbidity of DSM-III-R diagnosis in a birth cohort of 15 years olds. J Am Acad Child Adolesc Psychiatry 1993; 32: 1127-34
35. Farrington DP, Loeber R, Van Kammen WB. Longer-term criminal outcomes of hyperactivity-impulsivity-attention deficit and conduct problems in childhood. In: Robins LN, Rutter M, editors. Straight and devious pathways to adulthood. New York: Cambridge University Press, 1990: 62-81
36. Hinshaw SP, Lahey B, Hart L. Issues of taxonomy and comorbidity in the development of conduct disorder. Dev Psychopathol 1992; 5: 31-49
37. McGee R, Freehan M, Williams S, et al. DSM-III disorders from age 11 to 15 years. J Am Acad Child Adolesc Psychiatry 1992; 31: 50-9
38. Nottelman ED, Jensen PS. Comorbidity of depressive disorders in children and adolescents: rates, temporal sequencing, course and outcome. In: Esau CA, Petermann F, editors. Depressive disorders in children and adolescents: epidemiology, risk factors, and treatment. Northvale (NJ): Jason Aronson, 1999: 137-91
39. Arredondo DE, Butler SF. Affective comorbidity in psychiatrically hospitalized adolescents with conduct disorder of oppositional defiant disorder: should conduct disorder be treated with mood stabilizers? J Child Adolesc Psychopharmacol 1994; 4: 151-8
40. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1995; 56: 1088-96
41. Greene RW, Doyle AE. Toward a transactional conceptualization of oppositional defiant disorder: implications for assessment and treatment. Clin Child Fam Psychol Rev 1999; 2: 129-48
42. Cohen P, Flory M. Issues in the disruptive behavior disorders: attention deficit disorder without hyperactivity and the differential validity of oppositional defiant and conduct disorders. In: Widiger T, editor. DSM-IV source book. Vol. 4. Washington, DC: American Psychiatric Press, 1998: 463
43. Offord DR, Kraemer HC, Kazdin AE, et al. Lowering the burden of suffering from child psychiatric disorder: trade-offs among clinical, targeted and universal interventions. J Am Acad Child Adolesc Psychiatry 1998; 37: 686-94
44. Lahey BB, Loeber R, Hart EL, et al. Four year longitudinal study of conduct disorder in boys: patterns and predictors of persistence. J Abnormal Psychology 1995; 104: 83-93
45. Turgay A, Joseph LW, Duncan P, et al. The presence of oppositional defiant disorder in ADHD increases the risks for conduct disorder and mood disorders. Canadian Psychiatric Association Annual Scientific Meeting; 2001 Nov 15-18; Montreal (QC)
46. Turgay A, Morgan A, Mok L, et al. Chronic and serious aggressive behavior in children and adolescents are commonly associated with psychiatric disorders [abstract]. Paediatr Child Health 2001; 6 Suppl. A: 14
47. Coy K, Speltz ML, DeKleyn M, et al. Social-cognitive processes in preschool boys with and without oppositional defiant disorder. J Abnorm Psychol 2001; 29: 107-19
48. Coie JD, Dodge KA. The development of aggression and antisocial behavior. In: Eisenberg N, editor. Handbook of child psychology: social, emotional, and personality development. Vol. 3. New York: Wiley, 1998: 779-861
49. Offord D, Bennett K. Conduct disorder: long-term outcomes and intervention effectiveness. J Am Acad Child Adolesc Psychiatry 1994; 33: 1069-78
50. Webster-Stratton C. Strategies for helping early school-aged children with oppositional defiant and conduct disorders: the importance of home-school partnerships. School Psych Rev 1993; 22: 437-57
51. Greene RW, Ablon JS, Goring JC, et al. Effectiveness of collaborative problem solving in affectively dysregulated children with oppositional-defiant disorder: initial findings. J Consult Clin Psychol 2004; 72 (6): 1157-64
52. Brestan EV, Eyberg SM. Effective psychosocial treatments of conduct-disordered children and adolescents: 29 years, 82 studies, and 5272 kids. J Clin Child Psychol 1998; 27: 180-9
53. Kazdin AE. Parent management training: evidence, outcomes, and issues. J Am Acad Child Adolesc Psychiatry 1997; 36: 1349-56
54. Schumann EM, Foote RC, Eyberg SM, et al. Efficacy of parent-child interaction therapy: interim report of a randomized trial with short-term maintenance. J Clin Child Psychol 1998; 27: 34-45
55. MTA Cooperative Group. 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073-86
56. Turgay A, Jain U, Bedard AC, et al., on behalf of the Canadian ADHD Resource Alliance (CADDRA). Canadian AD/HD practice guidelines. Toronto (ON): Canadian AD/HD Resource Alliance, 2008
57. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006 Dec; 15 (8): 476-95
58. Newcorn J, Spencer T, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 240-8
59. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937; 94: 577-85
60. Conners CK, Eisenberg L, Barcai A. Effect of dextroamphetamine on children: studies on subjects with learning disabilities and school behavior problems. Arch Gen Psychiatry 1967; 17: 478-85
61. Waschbusch DA, Willoughby MT. Parent and teacher ratings on the IOWA Conners Rating Scale. J Psychopathol Behav 2007; 30: 180-92
62. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40: 168-79
63. Abikoff H, Gittelman R. Hyperactive children treated with stimulants: is cognitive training a useful adjunct? Arch General Psychiatry 1985; 42: 953-61
64. Richters JE, Arnold LE, Jensen PS, et al. NIMH collaborative multi-site multimodal treatment study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry 1995; 34: 987-1000
65. Hinshaw SP. Stimulant medication in the treatment of aggression in children with attention deficits. J Clin Child Psychol 1991; 12: 301-12
66. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006; 28: 1892-908
67. Jensen P. Standards of the use of stimulants. Paediatr Child Health 2004; 9 Suppl. B: 8-12B
68. Barkley RA, McMurray M, Edelbroch C, et al. Side effects of MPH in children with attention deficit hyperactivity disorder: a systemic placebo-controlled evaluation. Pediatrics 1990; 86: 184-92
69. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit- hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264-72
70. Pappadopulos E, Woolston S, Chait A, et al. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry 2006; 15: 27-39
71. Dunn D, Turgay A, Weiss M, et al. Use of plasma concentration to guide atomoxetine doses in ADHD patients [poster]. In: New Research Abstracts: American Psychiatric Association Annual Meeting; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005: 187
72. Turgay A. Atomoxetine in the treatment of children, adolescents and adults. Future Drugs 2006; 3 (1): 19-38
73. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord 2001; 5: 107-15
74. Conners CK. Conners' rating scales-revised: technical manual. New York: Multi-Health Systems, 1997
75. Kelsey DK, Sumner CR, Casat CD. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behaviour: a double-blind, placebo-controlled trial. Pediatrics 2004; 114 (1): e1-8
76. Michelson D, Faries D, Wenichke J, et al. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: e83
77. Spencer T, Biederman J, Heilingestein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11 (3): 251-65
78. Ryan ND. The pharmacologic treatment of child and adolescent depression. Psychiatr Clin North Am 1992; 15: 29-40
79. Turgay A, Ansari R. Major depression with ADHD in children and adolescents. Psychiatry 2006; 3: 20-32
80. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramine®: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1991; 30: 104-8
81. Conners CK, Cast CD, Guiltieri CT, et al. Bupropion hydrochloride in attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1996; 35: 1314-21
82. Simeon JG, Ferguson HB, Van Wyck Fleet J. Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 1986; 31: 581-5
83. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34:649-57
84. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit hyperactivity disorder: an open-label clinical trial. J Clinical Psychiatry 1996; 57: 184-9
85. Hedges D, Reimherr FW, Rogers A, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 1995; 31: 779-83
86. Connor DF, Barkley RA, Davis HT, et al. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000; 39: 15-25
87. Hunt D, Minderaa R, Cohen D. The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 1986; 22: 229-36
88. Connor DF, Fletcher KE, Swanson J. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551-9
89. Kemph JP, DeVane CL, Levin GM, et al. Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993; 32: 577-81
90. Campbell M, Adams P, Small A, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445-53
91. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000; 57: 649-54
92. Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorders in adolescents. Am J Psychiatry 1997; 154: 554-5
93. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650-6
94. Kafantaris V, Campbell M, Padron-Gayol MV, et al. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study [published erratum appears in Psychopharmacol Bull 1992; 28 (3): 220]. Psychopharmacol Bull 1992; 28: 193-9
95. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35: 480-90
96. Klein R, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1073-80
97. Findling RL, McNamara NK, Branicky LA, et al. A doubleblind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 509-16
98. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behavior disorders in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-46
99. Buitilaar JK, van der Gaag RJ, Chohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62: 239-48
100. Shea S, Turgay A, Jones S, et al. Risperidone in the treatment of behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634-41
101. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41 (9): 1026-36
102. Aman MG, Tassé MJ, Rojahn J, et al. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 1996; 17 (1): 41-57
103. Turgay A, Binder C, Snyder R, et al. Long term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 100 (3): e34
104. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004; 161: 677-84
105. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004; 14 (2): 243-54
106. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003; 20: 339-46
107. Yildiz A, Turgay A, Alpay M, et al. Observational data on the anti-agitation effect of risperidone tablets in emergency settings: a preliminary report. Int J Psychiatr Clin Pract 2003; 7: 217-21
108. Findling RL. Pharmacological options for treating disruptive behavior disorders. Paediatr Child Health 2004; 9 Suppl. B: 17-20B
109. Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 1995; 5: 157-66
110. Hunt RD, Capper S, O'Donnell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1990; 1: 87-102
111. Bukstein OG. Psychopharmacology of disruptive behavior disorders. In: Essau C, editor. Conduct and oppositional defiant disorders: epidemiology, risk factors and treatment. Mahwah (NJ): Lawrence Erlbaum Associates, 2003: 319-55
112. Wilens TE, Biederman J, Spencer TJ. Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder. J Am Acad Child Adolescent Psychiatry 1994; 33: 424-6
113. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58 (4): 527-36
114. Grob CS, Coyle JT. Suspected adverse methylphenidate-imipramine interactions in children. J Dev Behav Pediatr 1986; 7: 265-7
115. Carlson GA, Rapport MD, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol 1995; 5: 191-204
116. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of ADHD and comorbid depressive disorder. J Child Adolescent Psychopharmacol 1993; 5: 191-204
117. Drabick DAG, Gadow DG, Loney J. Source-specific oppositional defiant disorder: comorbidity and risk factors in referred elementary schoolboys. J Am Acad Child Adolesc Psychiatry 2007; 46: 92-101
118. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 126-41
119. Banaschewski T, Roessner V, Dittman RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13: 102-16